Tissue Regenix Group PLC Further Medicare Coverage Approval for DermaPure (7007M)
May 11 2015 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 7007M
Tissue Regenix Group PLC
11 May 2015
Tissue Regenix Group plc
Further Medicare Coverage Approval for DermaPure(R)
YORK, 11 May 2015 - Tissue Regenix Group plc (AIM:TRX) ("Tissue
Regenix" or "the Group"), the regenerative medical devices company,
today announces it has secured approval from CGS Medicare for
coverage of DermaPure(R) reimbursement. CGS covers the states of
Ohio and Kentucky and adds a further 1.9m Medicare beneficiaries
who can now receive the outstanding clinical benefits of the
product.
Tissue Regenix launched DermaPure(R) in 2014 and has since made
significant progress in not only demonstrating the clinical
benefits but also securing reimbursement for it. In March we
announced that DermaPure(R) had been approved for reimbursement
from the Novitas administrator and the combination of this and CGS
means that DermaPure(R) is now available to 10.8 million Medicare
beneficiaries across 14 states.
Today's announcement is evidence of the growing momentum behind
the product but also is further validation of TR's ability to
deploy its technology commercially.
Antony Odell, CEO of Tissue Regenix commented:
"We welcome CGS' decision to provide coverage in what is an
important additional step in achieving our strategic objective of
full commercialisation of DermaPure(R) in the United States. We
continue to work hard to raise awareness of the product based on
the strong clinical outcomes for patients and we are delighted to
get CGS coverage so soon after Novitas in March."
ENDS
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Tulchan Communications: +44 207 353 4200
Tom Buchanan
Victoria Huxster
Matt Low
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGURAAUPAGAR
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024